{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:31:36Z","timestamp":1740461496318,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,24]]},"DOI":"10.7759\/cureus.79567","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T16:42:46Z","timestamp":1740415366000},"source":"Crossref","is-referenced-by-count":0,"title":["Refractory Dermatitis Evolving Into Lupus Spectrum Disease in the Setting of Dupilumab Use"],"prefix":"10.7759","author":[{"given":"Jonathan M","family":"Joseph","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Kilgore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Culotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310370048","article-title":"Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates","volume":"19","author":"Obermoser G","year":"2010","unstructured":"Obermoser G, Sontheimer RD, Zelger B. Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus. 2010, 19:1050-70. 10.1177\/0961203310370048","journal-title":"Lupus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13082419","article-title":"The spectrum of cutaneous manifestations in lupus erythematosus: a comprehensive review","volume":"13","author":"Fija\u0142kowska A","year":"2024","unstructured":"Fija\u0142kowska A, K\u0105dziela M, \u017bebrowska A. The spectrum of cutaneous manifestations in lupus erythematosus: a comprehensive review. J Clin Med. 2024, 13:2419. 10.3390\/jcm13082419","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.984229","article-title":"Clinical aspects of cutaneous lupus erythematosus","volume":"9","author":"Elmgren J","year":"2022","unstructured":"Elmgren J, Nyberg F. Clinical aspects of cutaneous lupus erythematosus. Front Med (Lausanne). 2022, 9:984229. 10.3389\/fmed.2022.984229","journal-title":"Front Med (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-020-00906-8","article-title":"Cutaneous lupus erythematosus: progress and challenges","volume":"20","author":"Petty AJ","year":"2020","unstructured":"Petty AJ, Floyd L, Henderson C, Nicholas MW. Cutaneous lupus erythematosus: progress and challenges. Curr Allergy Asthma Rep. 2020, 20:12. 10.1007\/s11882-020-00906-8","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17177","article-title":"Recent findings about antimalarials in cutaneous lupus erythematosus: what dermatologists should know","volume":"51","author":"Teboul A","year":"2024","unstructured":"Teboul A, Arnaud L, Chasset F. Recent findings about antimalarials in cutaneous lupus erythematosus: what dermatologists should know. J Dermatol. 2024, 51:895-903. 10.1111\/1346-8138.17177","journal-title":"J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.07.027","article-title":"An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: a systematic review","volume":"82","author":"Shipman WD","year":"2020","unstructured":"Shipman WD, Vernice NA, Demetres M, Jorizzo JL. An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: a systematic review. J Am Acad Dermatol. 2020, 82:709-22. 10.1016\/j.jaad.2019.07.027","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16322","article-title":"Development of systemic lupus erythematosus after dupilumab treatment in a case of atopic dermatitis","volume":"49","author":"Okune M","year":"2022","unstructured":"Okune M, Okiyama N, Fukuzono M, Sasaki K, Nomura T. Development of systemic lupus erythematosus after dupilumab treatment in a case of atopic dermatitis. J Dermatol. 2022, 49:556-9. 10.1111\/1346-8138.16322","journal-title":"J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.03.013","article-title":"T helper 2 IL-4\/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17-type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases","volume":"142","author":"Bridgewood C","year":"2022","unstructured":"Bridgewood C, Wittmann M, Macleod T, et al.. T helper 2 IL-4\/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17-type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases. J Invest Dermatol. 2022, 142:2660-7. 10.1016\/j.jid.2022.03.013","journal-title":"J Invest Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2326480","article-title":"Dupilumab in real-life settings: a review of adverse events and their pathogenesis","volume":"23","author":"Camela E","year":"2024","unstructured":"Camela E, Giampetruzzi AR, De Pit\u00e0 O, Pallotta S, Russo F. Dupilumab in real-life settings: a review of adverse events and their pathogenesis. Expert Opin Drug Saf. 2024, 23:439-47. 10.1080\/14740338.2024.2326480","journal-title":"Expert Opin Drug Saf"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02574.x","article-title":"Lupus erythematosus tumidus: a series of 26 cases","volume":"45","author":"Vieira V","year":"2006","unstructured":"Vieira V, Del Pozo J, Yebra-Pimentel MT, Mart\u00ednez W, Fonseca E. Lupus erythematosus tumidus: a series of 26 cases. Int J Dermatol. 2006, 45:512-7. 10.1111\/j.1365-4632.2004.02574.x","journal-title":"Int J Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000002019","article-title":"Lupus erythematosus tumidus: clinical and pathological features in a series of 20 patients","volume":"44","author":"Maga\u00f1a M","year":"2022","unstructured":"Maga\u00f1a M, Castellanos G, Meurehg CC, Maga\u00f1a-Mainero MR. Lupus erythematosus tumidus: clinical and pathological features in a series of 20 patients. Am J Dermatopathol. 2022, 44:469-77. 10.1097\/DAD.0000000000002019","journal-title":"Am J Dermatopathol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/339171-refractory-dermatitis-evolving-into-lupus-spectrum-disease-in-the-setting-of-dupilumab-use","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T16:42:47Z","timestamp":1740415367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/339171-refractory-dermatitis-evolving-into-lupus-spectrum-disease-in-the-setting-of-dupilumab-use"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.79567","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,24]]}}}